Matthew Vanneman
Overview
Explore the profile of Matthew Vanneman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poorsattar S, Kumar N, Vanneman M, Kinney D, Jelly C, Bodmer N, et al.
J Cardiothorac Vasc Anesth
. 2024 Jun;
38(8):1641-1649.
PMID: 38876815
This special article is a continuation of an annual series for the Journal of Cardiothoracic and Vascular Anesthesia, highlighting the latest developments in the field of electrophysiology, particularly concerning cardiac...
2.
Choi C, Singh S, Cheung A, Vanneman M, Madhok J
J Cardiothorac Vasc Anesth
. 2024 Apr;
38(7):1539-1542.
PMID: 38637210
No abstract available.
3.
Kothari P, Kiwakyou L, Guenthart B, Vanneman M
J Cardiothorac Vasc Anesth
. 2024 Jan;
38(3):610-615.
PMID: 38228423
As the demand for heart allografts for transplantation continues to rise, ex vivo organ perfusion strategies are playing an increasingly important role in the preservation of organs from donation after...
4.
Vanneman M, Kothari P, Bodmer N, Convissar D, Desai G, Kumar N, et al.
J Cardiothorac Vasc Anesth
. 2022 Mar;
36(6):1526-1539.
PMID: 35248433
No abstract available.
5.
Vanneman M, Baker K, Saddawi-Konefka D
Med Educ
. 2017 Nov;
51(12):1293-1294.
PMID: 29124798
No abstract available.
6.
Vanneman M, Dranoff G
Nat Rev Cancer
. 2012 Mar;
12(4):237-51.
PMID: 22437869
During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer chemotherapies were initially identified through screens for compounds...
7.
Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, Homig-Holzel C, et al.
Cell
. 2012 Feb;
148(4):739-51.
PMID: 22341446
B cells infected by Epstein-Barr virus (EBV), a transforming virus endemic in humans, are rapidly cleared by the immune system, but some cells harboring the virus persist for life. Under...
8.
McMillin D, Delmore J, Negri J, Vanneman M, Koyama S, Schlossman R, et al.
Blood
. 2012 Feb;
119(15):e131-8.
PMID: 22289890
Conventional assays evaluating antitumor activity of immune effector cells have limitations that preclude their high-throughput application. We adapted the recently developed Compartment-Specific Bioluminescence Imaging (CS-BLI) technique to perform high-throughput quantification...
9.
Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, et al.
J Exp Med
. 2010 Sep;
207(10):2195-206.
PMID: 20837698
The inhibitor of apoptosis proteins (IAPs) have recently been shown to modulate nuclear factor κB (NF-κB) signaling downstream of tumor necrosis factor (TNF) family receptors, positioning them as essential survival...
10.
Ho V, Vanneman M, Kim H, Sasada T, Kang Y, Pasek M, et al.
Proc Natl Acad Sci U S A
. 2009 Sep;
106(37):15825-30.
PMID: 19717467
Through an immune-mediated graft-versus-leukemia effect, allogeneic hematopoietic stem cell transplantation (HSCT) affords durable clinical benefits for many patients with hematologic malignancies. Nonetheless, subjects with high-risk acute myeloid leukemia or advanced...